Welcome to Entry Card of Lysosomal Enzymes


Details of RareLED ID Assay_1043
Primary information
GENEPLA2G15
NUMBER OF ASSAY14
ASSAY IDs977610 588785 588787 159119 1137503 602351 159120 602353 602341 711871 602339 743137 588805 588803
Assay Name1. Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB,2. Late stage assay provider results from the probe development effort to identify inhibitors of pPAFAH: LC-MS/MS-based biochemical ABPP-MudPIT assay to determine selectivity of test compounds in the mouse brain membrane proteome,3. Late stage assay provider results from the probe development effort to identify inhibitors of pPAFAH: LC-MS/MS-based biochemical ABPP-MudPIT assay to determine selectivity of test compounds in the mouse brain soluble proteome,4. Inhibitory activity against phospholipase A2 enzyme; Not determined,5. Inhibition of Lypla3 in mouse Neuro2a cells at 3 nM after 4 hrs by ABPP-SILAC assay,6. Late stage assay provider results from the probe development effort to identify inhibitors of diacylglycerol lipase, beta (DAGLb): LCMS-based animal-based Activity-Based Protein Profiling (ABPP) MudPIT selectivity analysis for ABHD6,7. Inhibitory activity against phospholipase A2 enzyme,8. Late stage assay provider results from the probe development effort to identify inhibitors of diacylglycerol lipase, beta (DAGLb): LCMS-based animal-based Activity-Based Protein Profiling (ABPP) MudPIT selectivity analysis,9. Late stage assay provider results from the probe development effort to identify inhibitors of diacylglycerol lipase, beta (DAGLb): LCMS-based cell-based Activity-Based Protein Profiling (ABPP) SILAC selectivity analysis for ABHD6,10. Inhibition of LYPLA3 binding to FP-biotin in [12C][14N]-lysine, arginine and [13C6][15N2]-lysine, arginine labeled HEK293T cells at 20 uM after 1 hr by isotopic activity-based protein profiling-MudPIT assay,11. Late stage assay provider results from the probe development effort to identify inhibitors of diacylglycerol lipase, beta (DAGLb): LCMS-based cell-based Activity-Based Protein Profiling (ABPP) SILAC selectivity analysis,12. Late stage assay provider results from the extended probe development effort to identify inhibitors of LYPLA1 and LYPLA2: LCMS-based cell-based Activity-Based Protein Profiling (ABPP) SILAC selectivity analysis,13. Late stage assay provider results from the probe development effort to identify inhibitors of PME-1: ABHD10 inhibitor LC-MS/MS-based cell-based ABPP-SILAC assay,14. Late stage assay provider results from the probe development effort to identify inhibitors of PME-1: LC-MS/MS-based cell-based ABPP-SILAC assay
ACTIVITYSubstance BioActivity: 3598 Active, 421 Activity <= 1 nM, 2233 Activity <= 1 µM, 3598 Tested Substance BioActivity: 1 Active, 1 Tested Substance BioActivity: 1 Active, 1 Tested Substance BioActivity: 1 Tested Substance BioActivity: 3 Tested Substance BioActivity: 1 Active, 1 Tested Substance BioActivity: 1 Tested Substance BioActivity: 1 Active, 1 Tested Substance BioActivity: 1 Active, 1 Tested Substance BioActivity: 1 Tested Substance BioActivity: 1 Active, 1 Tested Substance BioActivity: 1 Active, 1 Tested Substance BioActivity: 1 Active, 1 Tested Substance BioActivity: 1 Probe, 1 Active, 1 Tested